Rybelsus in Australia: What the TGA approval actually means

What did @prescribeorpass actually say?

A pharmacist on TikTok explained that Rybelsus is an oral tablet form of semaglutide, the same active ingredient in Ozempic. She described how it uses absorption enhancers called SNAC to survive stomach acid, outlined the approved Australian indications, and was upfront that it is not PBS-listed and not approved for weight loss. She also flagged that oral absorption is less predictable than injection.

Credit where it is due: this is a more careful, nuanced take than most GLP-1 content circulating on TikTok right now. She named the drug correctly (brand name aside, more on that below), explained the mechanism, and did not oversell it as a weight loss solution. That matters when this category of drug is attracting enormous hype.

Does the science back this up?

Mostly, yes. The SNAC mechanism is real, well-documented, and the reason oral semaglutide works at all. Bioavailability is still low compared to injection, which has real clinical consequences.

Rybelsus uses sodium N-(8-(2-hydroxybenzoyl) aminocaprylate, shortened to SNAC, as an absorption enhancer. SNAC temporarily raises local gastric pH and increases mucosal permeability, allowing semaglutide to absorb across the stomach lining before enzymes degrade it. The PIONEER clinical trial program, which ran across multiple large randomised controlled trials, confirmed the drug lowers HbA1c and body weight in type 2 diabetes. Davies et al. (2019, The Lancet) showed oral semaglutide 14mg reduced HbA1c by 1.4 percentage points versus placebo. Bioavailability is roughly 1 percent, compared to subcutaneous semaglutide which approaches 89 percent (Bækdal et al., 2021, Clinical Pharmacokinetics). That gap is not trivial and the pharmacist is right to flag absorption variability as a practical limitation.

What did they get wrong (or right)?

One factual error stands out: she consistently called the drug "Robulsus" throughout the video. The correct brand name is Rybelsus. That is not a minor slip when people are going to search that name. Everything else is largely accurate.

She correctly described the dosing titration starting at 3mg, moving to 7mg, and potentially up to 14mg. That matches the TGA-approved prescribing information. Her description of the administration requirements, empty stomach, small sip of water, 30-minute wait, is accurate and clinically important. Skipping those steps meaningfully reduces absorption, as Granhall et al. (2018, Clinical Pharmacokinetics) demonstrated when food and fluid volume were varied. She also correctly stated the cardiovascular indication, which comes from the PIONEER 6 trial (Husain et al., 2019, New England Journal of Medicine). Her comparison of side effects to Ozempic is reasonable given the shared active ingredient, though gastrointestinal events can differ in frequency between routes of administration.

What should you actually know?

If you are considering Rybelsus, the absorption issue is not a minor footnote. It is the central practical challenge with this drug, and the pharmacist deserves credit for being direct about it.

Oral semaglutide's low bioavailability means dose-to-dose variability is higher than with the injection. Any food, coffee, or even excess water within that 30-minute window can substantially reduce how much drug actually reaches your bloodstream. For people managing type 2 diabetes who already take morning medications, this timing requirement can be genuinely difficult to maintain consistently. The drug is not PBS-listed in Australia, which means out-of-pocket costs are significant. It is also not approved by the TGA for weight management. Wegovy, the higher-dose injectable semaglutide, carries that indication. Rybelsus does not. If a prescriber or compounding pharmacy is promoting oral semaglutide specifically for weight loss in Australia, that is off-label use and patients deserve to know that clearly before agreeing to it.

Bottom line

This is one of the better GLP-1 explainer videos doing the rounds right now. The pharmacist got the mechanism right, flagged the limitations honestly, and did not hype the drug for weight loss. The brand name error is sloppy and should be corrected given how many people will try to look this up. The broader point she makes, that a weekly subcutaneous injection with more predictable absorption may be a more reliable choice for most people, is clinically defensible and refreshingly honest for a platform that rarely admits when the pill is not the best option.